Recent

% | $
Quotes you view appear here for quick access.

PIMCO Total Return Active ETF Message Board

mikhail_gorbachev_1 3 posts  |  Last Activity: Apr 19, 2015 4:38 PM Member since: Mar 22, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • mikhail_gorbachev_1 mikhail_gorbachev_1 Apr 19, 2015 4:38 PM Flag

    Yes, it was form today at the European conference. Go to Ariad web site for further details..

  • mikhail_gorbachev_1 mikhail_gorbachev_1 Apr 19, 2015 3:55 PM Flag

    Conclusion:
    AP26113 inhibits all 17 clinically and preclinically observed crizotinib-, ceritinib-, and/or alectinib-resistant ALK mutants tested in vitro, has potent effects on the recalcitrant G1202R mutant in vivo and has activity in an orthotopic brain model.
    These results suggest AP26113 may effectively address a broad range of resistance mechanisms identified for other ALK TKIs. AP26113 is currently in a global phase 2 registration trial in patients with locally advanced or metastatic ALK+ NSCLC who were previously treated with crizotinib (NCT02094573).

    The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models .

    Sentiment: Strong Buy

  • Conclusion:
    AP26113 inhibits all 17 clinically and preclinically observed crizotinib-, ceritinib-, and/or alectinib-resistant ALK mutants tested in vitro, has potent effects on the recalcitrant G1202R mutant in vivo and has activity in an orthotopic brain model.
    These results suggest AP26113 may effectively address a broad range of resistance mechanisms identified for other ALK TKIs. AP26113 is currently in a global phase 2 registration trial in patients with locally advanced or metastatic ALK+ NSCLC who were previously treated with crizotinib (NCT02094573).

    The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models .

    ...

BOND
106.47+0.08(+0.08%)Jul 2 4:00 PMEDT